Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring

Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia

(2022) Lindsay Okubo et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Cefepime-induced neurotoxicity: systematic review

(2022) Gozun Maan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation Of Individualized Cefepime Dosing Strategy Using Population Pharmacokinetics

(2021) Yoonsun Mo et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics

(2021) Mohammad H. Alshaer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing

(2020) Mohammad H. Al-Shaer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/pharmacodynamic target in Asian ICU population: a prospective observational study

(2019) Chien-Chih Wu et al.   Infection and Drug Resistance

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update

(2018) Randy A. Taplitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens

(2017) Nathaniel J. Rhodes et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-Analysis

(2017) Nikolaos Andreatos et al.   Open Forum Infectious Diseases

Management of febrile neutropaenia: ESMO Clinical Practice Guidelines†

(2016) J. Klastersky et al.   ANNALS OF ONCOLOGY

The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study

(2016) Masaki Fujita et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

(2016) Lindsey Robert Baden et al.   Journal of the National Comprehensive Cancer Network

Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation

(2016) Laura Whited et al.   PHARMACOTHERAPY

Relationship between PK/PD of Cefepime and Clinical Outcome in Febrile Neutropenic Patients with Normal Renal Function

(2016) Yoshiko Yamashita et al.   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Adequacy of High-Dose Cefepime Regimen in Febrile Neutropenic Patients with Hematological Malignancies

(2015) Fekade Bruck Sime et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia

(2013) D. Averbuch et al.   HAEMATOLOGICA

Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

(2011) Alison G. Freifeld et al.   CLINICAL INFECTIOUS DISEASES

Management of febrile neutropenia: ESMO Clinical Practice Guidelines

(2010) J. de Naurois et al.   ANNALS OF ONCOLOGY

Meta‐Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use

(2010) Peter W. Kim et al.   CLINICAL INFECTIOUS DISEASES

Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia

(2009) A. M. Nicasio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY